These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8830059)

  • 1. Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
    Markman M
    J Cancer Res Clin Oncol; 1996; 122(9):568-9. PubMed ID: 8830059
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
    King TC; Estalilla OC; Safran H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and angiogenesis in non-small-cell lung cancer.
    Giatromanolaki A; Koukourakis MI
    Br J Cancer; 1998 Mar; 77(5):850-2. PubMed ID: 9514069
    [No Abstract]   [Full Text] [Related]  

  • 4. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients.
    Andjelkovic T; Bankovic J; Stojsic J; Milinkovic V; Podolski-Renic A; Ruzdijic S; Tanic N
    Transl Res; 2011 Jan; 157(1):19-28. PubMed ID: 21146147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
    Oncology (Williston Park); 2000 Aug; 14(8 Suppl 7):7-47. PubMed ID: 11021302
    [No Abstract]   [Full Text] [Related]  

  • 6. Modification of tumor suppressor gene expression in non-small cell lung cancer (NSCLC) with a retroviral vector expressing wildtype (normal) p53.
    Roth JA
    Hum Gene Ther; 1996 May; 7(7):861-74. PubMed ID: 8860838
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
    Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
    Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Nixon NA; Khan OF; Imam H; Tang PA; Monzon J; Li H; Sun G; Ezeife D; Parimi S; Dowden S; Tam VC
    Cancer; 2017 Dec; 123(23):4672-4679. PubMed ID: 28817175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease.
    Behrens C; Travis LB; Wistuba II; Davis S; Maitra A; Clarke EA; Lynch CF; Glimelius B; Wiklund T; Tarone R; Gazdar AF
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1027-35. PubMed ID: 11045784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
    Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Annual meeting of the American Association for Cancer Research].
    Lavelle F; Armand JP
    Bull Cancer; 2000 Jun; 87(6):507-11. PubMed ID: 10903792
    [No Abstract]   [Full Text] [Related]  

  • 12. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and regulation of tumor suppressor gene maspin in breast cancer.
    Maass N; Nagasaki K; Ziebart M; Mundhenke C; Jonat W
    Clin Breast Cancer; 2002 Oct; 3(4):281-7. PubMed ID: 12425757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer.
    Wick W; Petersen I; Schmutzler RK; Wolfarth B; Lenartz D; Bierhoff E; Hümmerich J; Müller DJ; Stangl AP; Schramm J; Wiestler OD; von Deimling A
    Oncogene; 1996 Mar; 12(5):973-8. PubMed ID: 8649814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.
    Yuan A; Yu CJ; Luh KT; Kuo SH; Lee YC; Yang PC
    J Clin Oncol; 2002 Feb; 20(4):900-10. PubMed ID: 11844810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highlights in NSCLC from the 2014 American Society of Clinical Oncology annual meeting.
    Clin Adv Hematol Oncol; 2014 Oct; 12(10 Suppl 18):7-16. PubMed ID: 25768032
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet.
    Macchiarini P; Fontanini G; Dulmet E; de Montpreville V; Chapelier AR; Cerrina J; Ladurie FL; Dartevelle PG
    Ann Thorac Surg; 1994 Jun; 57(6):1534-9. PubMed ID: 7516646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].
    Pietrasz D; Pécuchet N; Fabre E; Blons H; Chevalier L; Taly V; Laurent-Puig P; Bachet JB
    Bull Cancer; 2016 Jan; 103(1):55-65. PubMed ID: 26790710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.